FORM 8.1(a) & (b) (Opening Position Disclosure)

(a) 

Full name of discloser:

Alkermes plc

(b)

Owner or controller of interests and short
positions disclosed, if different from 1(a):

N/A

(c)

Name of offeror/offeree in relation to whose
relevant securities this form relates:

Avadel
Pharmaceuticals 
plc

(d)

Is the discloser the offeror or the offeree?

OFFEROR

(e) 

Date position held:

3 November
2025

(f)  

In addition to the company in 1(c) above, is
the discloser also making disclosures in
respect of any other party to the offer?

N/A

Details of any interests and short positions (including directors'
and other employee options) of any person acting in concert with
the party making the disclosure:

Interests of J.P. Morgan (together with its members of staff under Rule 
3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to
Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:

Party

Class of 
Relevant
Security

Number of 
ordinary
shares held
at midnight
(ET) on
3 November
2025

Percentage 
of total
issued share
capital
(rounded)

55I, LLC

Ordinary 
shares of
US$0.01
each

53

0.0001 %

JPMorgan
Chase Bank,
National
Association

Ordinary 
shares of
US$0.01
each

13,500

0.0139 %

TOTAL

13,553

0.0139 %

Details of any open stock-settled derivative positions (including traded 
options), or agreements to purchase or sell relevant securities, should
be given on a Supplemental Form 8.

Details of any indemnity or option arrangement, or any agreement
or understanding, formal or informal, relating to relevant securities
which may be an inducement to deal or refrain from dealing entered 
into by the party to the offer making the disclosure or any person
acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state
"none"

Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated. 

Is a Supplemental Form 8 attached?   

YES/NO

Date of disclosure:

5 November 2025

Contact name:

Sandy Coombs, Alkermes

Telephone number:

+1 781 609 6377

Public disclosures under Rule 8.1 of the Rules must be made to a 
Regulatory Information Service.